熱點掃描 | 互聯網醫療板塊漲幅靠前，京東健康漲超15%
uSMART盈立智投3月29日消息，截止發稿，港股三大指數漲跌互現，恆生指數上漲0.49%，報21793.14點，成交額633.84億；國企指數上漲0.73%，報7450.44點，成交額258.22億；紅籌指數下跌0.27%，報3934.41點，成交額22.778億。
互聯網醫療板塊漲幅靠前，京東健康漲超15%，阿裏健康漲超8%，平安好醫生漲超4%；
煤炭股延續昨日漲勢，南戈壁漲超6%，中國神華漲超4%，伊泰煤炭漲超3%，兗礦能源漲近3%；
旅遊股拉昇，新世紀集團、國家聯合資源漲超5%，攜程、太陽城集團漲超4%，同程旅行上漲3.53%，香港中旅漲超1%；
電力股普跌，華潤電力、華電國際電力、華能國際電力跌超2%，大唐發電跌近1%；
熱門股
歌禮制藥漲近2%，報5.78港元，歌禮制藥董事會欣然宣佈公司2款在研抗癌新藥，口服PD-L1小分子抑制劑ASC61和脂肪酸合成酶(FASN)抑制劑ASC60的最新臨牀前研究結果入選2022年美國癌症研究協會(AACR)年會(“2022年AACR年會”)；
凱萊英現漲4.86%，報271.4港元，凱萊英28日發佈公告，公司擬與海河凱萊英基金、高瓴祈睿、珠海岱恆等簽署投資協議，各投資方在凱萊英生物發展完成對凱萊英生物的全資收購後，對凱萊英生物發展進行投資並認購其新增註冊資本。各投資方將按照投資協議約定分期向凱萊英生物發展合計增資不超過約25.34億元。凱萊英生物發展未來將定位成爲凱萊英醫藥集團中包括大分子藥物、抗體偶聯藥物、細胞基因治療藥物以及mRNA藥物等在內的獨家合同研發生產服務（CDMO）企業；
稻草熊娛樂漲4.48%%，報4.2港元，公司25日發佈2021全年業績，母公司擁有人應佔溢利1.69億元，同比增加831.1%，經調整純利1.94億元，同比增加48.3%。每股基本盈利25.1分，同比增加445.65%，不派息。期內，公司收入爲17.03億元，同比增加78.8%，毛利爲5.16億元，同比增加98.7%；截至報告期末，公司資產淨值17.73億元，同比增加689.4%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
